Law Offices Encourages Medpace Shareholders to Inquire About Securities Fraud Lawsuit

Class action alleges Medpace misled investors about its book-to-bill ratio and backlog cancellations.

Apr. 9, 2026 at 4:06pm

Got story updates? Submit your updates here. ›

The Law Offices of Frank R. Cruz has filed a class action lawsuit on behalf of Medpace Holdings, Inc. (NASDAQ: MEDP) shareholders who purchased the company's common stock between April 22, 2025 and February 9, 2026. The lawsuit alleges that Medpace made materially false and misleading statements about its projected book-to-bill ratio and the impact of cancellations on its business.

Why it matters

Medpace is a clinical research organization that provides drug and medical device development services. The lawsuit alleges the company misled investors about key financial metrics, which could have significant implications for the company and its shareholders.

The details

The lawsuit claims Medpace consistently overstated its projected book-to-bill ratio for Q4 2025, failed to disclose the impact of cancellations on that metric, and reassured investors that cancellations were not a sign of a weak business environment. However, when Medpace reported Q4 2025 results, it revealed a book-to-bill ratio of 1.04, well below its guidance of 1.15, which the company attributed to high backlog cancellations.

  • The class period covers April 22, 2025 to February 9, 2026.
  • Medpace reported its Q4 2025 results on February 9, 2026.
  • Medpace's stock price fell 15.9% on February 10, 2026 in response to the Q4 results.

The players

Law Offices of Frank R. Cruz

A law firm that has filed a class action lawsuit against Medpace on behalf of the company's shareholders.

Medpace Holdings, Inc.

A clinical research organization that provides drug and medical device development services.

Got photos? Submit your photos here. ›

What’s next

Medpace shareholders have until June 5, 2026 to file a lead plaintiff motion in the class action lawsuit.

The takeaway

This case highlights the importance of accurate financial reporting and disclosure, especially for companies in the highly regulated healthcare and pharmaceutical industries. Investors will be closely watching the outcome of this lawsuit and any potential impact on Medpace's business and reputation.